EverQuote Shorts Hold Firm Into November Earnings

EverQuote heads into its November 2 earnings with short interest at 21.6% of the free float, a structurally heavy short position that has barely moved despite the stock gaining 10% this week.

The positioning story is the central tension. Short interest has crept up 5% over the past month to just under 7 million shares, and the ORTEX short score sits at 71, well into elevated territory, where it has been anchored for weeks. Yet the borrow market tells a different story: availability is at 291%, meaning roughly three shares are available to borrow for every two already lent out, and cost to borrow is negligible at 0.50%. Bears can add to positions cheaply and easily. That combination, heavy existing short interest with no squeeze pressure, suggests the short side is comfortable rather than cornered. Options traders lean the same way. The put/call ratio has dropped to 0.40, more than one standard deviation below its 20-day average of 0.44, meaning options activity is skewing toward calls ahead of the print. That's a mild tilt toward upside hedging, though at 52-week lows the PCR has reached 0.09, so this week's call-leaning reading is far from extreme.

The Street is broadly constructive but the data is now two months stale, the most recent analyst action dates to August 24. JP Morgan initiated at Overweight with a $29 target that week, and after Q2 results, B. Riley raised to $34 while Needham lifted to $30. All three cover with buy-equivalent ratings, putting the mean target at $29.50, roughly 30% above the current price of $22.72. The valuation is undemanding: the stock trades at 7.6x trailing earnings and 4.7x EV/EBITDA, with the EV/EBIT factor scoring in the 82nd percentile of the universe. The bull case rests on auto insurance carrier spending: 32% year-on-year growth in that vertical, driven by carriers with improving loss ratios ploughing more into customer acquisition. The bear case centres on VMM margin compression, which fell 350 basis points to 25.3%, and guidance that came in below consensus for the first quarter of 2026, raising the question of whether the margin pressure is cyclical or structural.

An activist is on the register and is worth noting. David Blundin holds 18.4% of the class on a Schedule 13D/A, down from 21.4% at the prior filing in August 2025. The reduction in the disclosed stake is the more relevant fact: he has trimmed, though remains the largest single holder by a meaningful margin. Link Equity Partners holds a further 17.5%. BlackRock has added, reaching 10.8% as of September 30, and Allspring Global Investments filed a fresh 13G on October 7, disclosing a 5.9% position after adding 442,000 shares. As always with 13D/G filings, stakes are as last disclosed and holders who drop below 5% may not file again.

Insider selling has been consistent but modest. Every open-market trade in the past 90 days has been a sale, totalling a net $1.7 million across the CEO, CFO, CTO, Chief Accounting Officer, and two directors. All were made under pre-arranged 10b5-1 plans, which reduces their signalling value as a measure of executive conviction. The CEO sold $406,000 worth on October 1; the CTO sold a combined $97,000 across two transactions in early October. These are plan-driven disposals, not discretionary moves.

The last earnings print, in August, sent the stock down 5.4% on the day before recovering 1.3% over the following five sessions. With the next report 12 days away, the dynamic to watch is whether the VMM trajectory has stabilised: the bull and bear cases for November both hinge less on revenue growth, which has been strong, and more on what the margin line looks like as carrier spending patterns normalise.